Definitive Contract 75N93019C00044
Award Date
9/30/19
Potential Completion Date
9/29/25
Potential Value
$11M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Boston, MA 02115, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $8,330,482.00 cost-reimbursement definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services (HHS), to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The contract is for the Vaccine Adjuvant Discovery Program (VADP), which supports the identification and characterization of novel, effective and safe vaccine adjuvants. The contract has a period of...
This is a $3,300,145.00 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to The Children's Hospital Corporation, doing business as Boston Children's Hospital, a non-profit pediatric teaching hospital and research center. The contract is for the Vaccines Adjuvant Development Program in Infectious and Immune Mediated Diseases, with a period of performance through September...
This is a definitive, cost-no-fee federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to The Children's Hospital Corporation, doing business as Boston Children's Hospital. The $13,600,565.07 contract is for an "ADJUVANT DEVELOPMENT PROGRAM" and has an ultimate completion date of September 29, 2025. Boston Children's Hospital, a non-profit pediatric teaching hospital and research...
This $24,785,826.00 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to the non-profit Children's Hospital Corporation, doing business as Boston Children's Hospital. The contract is to develop innovative and safe multivalent anti-opioid vaccines that protect against heroin and fentanyl. The work will involve activities such as adjuvant...
This is a $4,259,653.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), to Inimmune Corp, a biotechnology company, for the development of a synthetic AS01-like adjuvant system for influenza vaccines. The contract has an ultimate completion date of September 29, 2028 and is a cost-type contract without a fee. This contract is not set aside...
This federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to The Children's Hospital of Philadelphia (CHOP) for "Targeted Clinical Research to Address Select Viral Infections." The $5,835,169.39 definitive contract is for a 7-year period ending in May 2024. It does not have a set-aside designation.
Under this contract, CHOP leads a multi-site observational study on human...
This definitive contract from the Department of Health and Human Services' National Institutes of Health and National Institute of Allergy and Infectious Diseases (HHS-NIH-NIAID) is valued at $600,000 to Antagen Biosciences Inc., doing business as Antagen Pharmaceuticals, for work in Boston, MA from September 2020 through August 2022. The contract was awarded under the Small Business Innovation Research (SBIR) program's total small business set-aside solicitation seeking proposals on topics...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $6,690,024.90 definitive, cost-no-fee contract to Vaxine PTY LTD, a for-profit organization located in Australia, for an Adjuvant Development Program. The contract, which has an ultimate completion date of February 10, 2025, was awarded on September 10, 2018 and does not have a set-aside designation. The contract aims to support the development of vaccine adjuvants, which are compounds that enhance the immune response...
This is a $18,576,013.05 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Access To Advanced Health Institute (AAHI), a non-profit biotech research institute located in Seattle, Washington. The contract is for the development of vaccine candidates to address biodefense, antimicrobial resistant infections, and emerging infectious diseases. AAHI, which does...
This is a $10,725,896 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Oregon Health & Science University (OHSU) to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines. The contract supports research to develop new vaccine adjuvants that leverage the innate and adaptive immune system to enhance protection against pathogens relevant to human disease. The contract does not have a set-aside...